TrialThe Lancet. Oncology2013

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Gary K Schwartz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.